Results 171 to 180 of about 21,372 (208)

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus. [PDF]

Curr Oncol
Schuh AC, Chornenki N, Elemary MA, Elsawy M, Houston BL, Leber B, Mozessohn L, Sabloff M, Salter B, Sanford D, Brandwein J.   +10 more
europepmc   +1 more source

Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models. [PDF]

J Clin Invest
Chen X, Zhang L, Yan B, Sui Y, Ma W, Zhao H, Wang Y, Yang K, Ma J, Tang B, Zhang Y, Zhu X.   +11 more
europepmc   +1 more source

G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia. [PDF]

Leukemia
Chen Z, Cai Y, Wang Y, Lai X, Yan X, Wang X, Tu F, Wu W, Gao H, Zheng Y, Zeng Y, Li Y, Li J, Pan L, Wang P, Ji W, Xu L, Wang S.   +17 more
europepmc   +1 more source

Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy. [PDF]

Pharmaceuticals (Basel)
Shams UA, Inayat F, Zeb MA, Maryam, Shams S, Ullah MJ, Jiménez-Morales S.   +6 more
europepmc   +1 more source

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival. [PDF]

Ann Hematol
Ginosyan AA, Ashouri K, Cheng J, Ford L, Baya M, Humayun L, Hong D, Huang E, Kim G, Tang B, Hom B, Ireland R, Siddiqi I, Ali A, Woan K, Tam EL, Yaghmour G.   +16 more
europepmc   +1 more source

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source

Comment on AlAsmari et al. Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-κB and BCL-2 Pathway. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 6260. [PDF]

Int J Mol Sci
Trela BA, Guffroy MR.
europepmc   +1 more source

Treatment of Cold Agglutinin Syndrome Secondary to Chronic Lymphocytic Leukemia With Sutimlimab and Obinutuzumab-Venetoclax. [PDF]

Case Rep Hematol
Lap CJ, Broome CM.
europepmc   +1 more source

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia. [PDF]

Cancer
Farhat A, El Hajjar G, Kantarjian H, Sasaki K, Short NJ, Cuglievan B, Loghavi S, Patel K, Bataller A, Jen WY, Yilmaz M, Montalban-Bravo G, Hammond D, Pemmaraju N, Daver N, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, DiNardo CD, Issa GC.   +21 more
europepmc   +1 more source

A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo. [PDF]

Sci Adv
Diepstraten ST, Deng Y, Potts MA, Heidersbach A, König C, Dorighi KM, Tai L, Kueh AJ, Whelan L, Chang C, Brown F, Kelly GL, Fortin JP, Haley B, La Marca JE, Herold MJ.   +15 more
europepmc   +1 more source